Table 1.
Clinical and laboratory findings in 118 patients with portal vein thrombosis
| Parameters | Extrahepatic portal vein obstruction (n = 50) | Cirrhosis and tumor- related portal vein thrombosis (n = 68) |
| Male:Female | 33:17 | 51:17 |
| Age (yr)2 | 25 (9-40) | 52 (23-80) |
| Hematemesis | 36 (72%) | 10 (14.7%) |
| Hypersplenism | 30 (60%) | 6 (8.8%) |
| Pain abdomen | 18 (36%) | 42 (61.8%) |
| Abdominal distension | 8 (16%) | 36 (52.9%) |
| Awareness of splenomegaly | 6 (20%) | - |
| Jaundice | 5 (10%) | 18 (26.5%) |
| Cholangitis | 1 (2%) | 5 (7.4%) |
| Splenomegaly2 cm1 | 4 (2-14); (n = 35) | 2 (2-4); (n = 7) |
| Hepatomegaly2 cm1 | 2 (1-3); (n = 8) | 3 (2-6); (n = 16) |
| Etiology | ||
| Hepatocellular carcinoma | - | 31 |
| Cirrhosis liver | - | 18 |
| Metastases liver | - | 6 |
| Pancreatic carcinoma | - | 7 |
| Cholangio carcinoma | - | 3 |
| Carcinoma gallbladder | - | 2 |
| Duodenal carcinoid | - | 1 |
| Esophageal Varices | 35 (70%) | 32 (47%) |
| Gastric Varices | 11 (22%) | 3 (4.4%) |
| GoVI | 1 | 2 |
| GoV2 | 8 | 1 |
| IGV1 | 2 | |
| Portal hypertensive gastropathy | 8 (16%) | 48 (70.4%) |
| Mild | 6 | 40 |
| Severe | 2 | 8 |
| Hemoglobin2 (gm/dL) | 7.2 (1.7-14.7) | 8.0 (6.0-11.6) |
| Total leucocyte count2 (103/mm3) | 2.9 (1.0-6.8) | 6.4 (1.36-29.71) |
| Platelet count2 (105/mm3) | 0.49 (0.14-1.54) | 1.52 (0.29-2.59) |
| Bilirubin2 (mg/dL) | 1.0 (0.4-18.5) | 1.2 (0.5-15.1) |
| AST2 (U/L) | 38 (18-231) | 79 (39-961) |
| ALT2 (U/L) | 34 (18-254) | 65 (18-1146) |
| SAP2 (U/L) | 264 (110-2849) | 348 (140-3140) |
| Protein/albumin2 (mg/dL) | 6.8 (5-7.5)/3.8 (3-4) | 6 (5.3-8)/3.3 (2-4.6) |
| Prothrombin time prolongation2 (seconds) | 2 (1-3) | 4 (2-14) |
| Portal biliopathy | 4 (8%) | |
| Choledocholithiasis | 2 | |
| CBD stricture | 2 | |
| EVL sessions2 | 3 (2-4) | - |
| Glue injection (n) | 4 | - |
| Superior mesenteric vein | 11 (22%) thrombosis | 6 (8.8%) |
| Inferior vena cava thrombosis | 4 (8%) | 3 (4.4%) |
| Splenic vein thrombosis | 4 (8%) | 4 (5.6%) |
| Deep vein thrombosis | - | 1 (1.4%) |
| HBsAg | 0 | 27 (39.7%) |
| Anti-HCV | 0 | 3 (4.4%) |
1
Centimeter below costal margin;
2
Median (range).